Stifel Reiterates Buy Rating on Renalytix AI Plc. (RNLX) After Medicare Delay

March 15, 2021 9:27 AM EDT
Get Alerts RNLX Hot Sheet
Price: $25.64 -3.9%

Rating Summary:
    1 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Stifel analyst Daniel Arias reiterated a Buy rating and $30.00 price target on Renalytix AI Plc. (NASDAQ: RNLX) after the Centers for Medicare & Medicaid Services (CMS) announced that it will delay the implementation of the Medicare Coverage for Innovative Technology (MCIT) program for 60 days in what appears to be a part of a regulatory freeze put in place by the new Biden administration.

The analyst stated "While the development no doubt introduces some uncertainty to a process that has driven meaningful enthusiasm for shares since January and it is unclear whether this triggers changes in the scope of the program, the risk to RNLX looks low at the moment - most notably because a May implementation would still come ahead of an expected calendar 2H21 FDA approval (which would trigger coverage and reimbursement) much the same way a March implementation would."

For an analyst ratings summary and ratings history on Renalytix AI Plc. click here. For more ratings news on Renalytix AI Plc. click here.

Shares of Renalytix AI Plc. closed at $28.00 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Stifel, FDA